CT26.CL25

CT26.CL25
CT26.CL25
The CT26.CL25 cell line is a murine colon carcinoma model derived from the parental CT26 cell line, ...
17 303,00Kč
Cena bez DPH: 14 300,00Kč
  • Výrobce: Cytion
  • Kód výrobce: CYT-305353

Dostupné možnosti

The CT26.CL25 cell line is a murine colon carcinoma model derived from the parental CT26 cell line, which is a chemically induced, undifferentiated colon carcinoma originating from BALB/c mice. CT26.CL25 has been genetically modified to express the β-galactosidase (β-gal) protein, making it an excellent model for studying tumor immunology and immunotherapy, particularly in the context of tumor-associated antigens (TAAs). This modification allows for specific immunological studies targeting β-gal as a neoantigen, facilitating research into the mechanisms of tumor immune evasion and the development of cancer vaccines or adoptive cell therapies. CT26.CL25 has been employed in preclinical models to investigate immune responses and the efficacy of immunotherapies, such as the use of dendritic cells (DCs) loaded with tumor-associated antigens. Studies have shown that immunization strategies using DCs pulsed with peptides derived from retroviral antigens, like gp70, can elicit robust anti-tumor immune responses. In experimental models, the activation of CD8+ cytotoxic T lymphocytes (CTLs) specific for gp70 was observed, demonstrating the cell line's utility in testing immunotherapeutic approaches. However, the immunization with such peptide-loaded DCs has shown limitations, particularly in treating established metastases, highlighting the challenges in translating prophylactic immune responses into therapeutic efficacy. Additionally, CT26.CL25 is often used in research to test the efficacy of combined immunotherapy approaches, such as the use of immune checkpoint inhibitors or cancer vaccines. For instance, studies have evaluated the impact of metronomic chemotherapy combined with immune checkpoint inhibitors, where the induction of immunogenic cell death (ICD) in CT26.CL25 has been crucial for enhancing the anti-tumor immune response. These investigations have demonstrated that targeting immune checkpoints can synergize with chemotherapy to increase tumor rejection rates and establish long-term immunological memory. Intestine cancer cell lines, Colon, Adenocarcinoma, Growth Conditions: Adherent, Biosafety level: BSL 1
Technické specifikace
Doprava a skladování Adherent
Poznámka k dopravě Dopravné k objednávce je závislé na BLS třídě dodávaných produktů a na konkrétních podmínkách přepravy. Před objednáním nás prosím kontaktujte a naši pracovníci Vám vždy cenu dopravy vyčíslí pro každý jednotlivý případ. Každá viála obsahuje celkem přibližně 3 miliony adherentních buněk nebo 5 milionů suspenzních buněk s typickou životaschopností po rozmrazení v rozmezí 80-95 %. Tyto údaje slouží jako obecné vodítko; ačkoli dodržujeme přísné normy kvality, přesné počty buněk a životaschopnost se mohou lot-to-lot lišit a nejsou zaručeny.
Vlastnosti
Původ Mouse
Specifita Intestine cancer cell lines
6 720,00Kč
Cena bez DPH:5 553,72Kč
Přidat do nabídky
149,00Kč
Cena bez DPH:123,14Kč
Přidat do nabídky
149,00Kč
Cena bez DPH:123,14Kč
Přidat do nabídky
191,00Kč
Cena bez DPH:157,85Kč
Přidat do nabídky
166,00Kč
Cena bez DPH:137,19Kč
Přidat do nabídky
159,00Kč
Cena bez DPH:131,41Kč
Přidat do nabídky
21 821,00Kč
Cena bez DPH:18 033,88Kč
Přidat do nabídky
12 497,00Kč
Cena bez DPH:10 328,10Kč
Přidat do nabídky
31 297,00Kč
Cena bez DPH:25 865,29Kč
Přidat do nabídky
21 821,00Kč
Cena bez DPH:18 033,88Kč
Přidat do nabídky